© 2019 by Biotech Stock Report

Search
  • Biotech Stock Report

BioSig Technologies Inc. Issues 2019 Shareholder Letter

Company provides updates on recent developments and highlights plans for future growth


Santa Monica, CA, Feb. 12, 2019 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM), a medical device company developing a proprietary biomedical signal processing platform designed to address an unmet technology need for the electrophysiology (EP) marketplace, today announced that the Company has issued their February 2019 letter to its shareholders, highlighting their recent uplisting to the Nasdaq Capital Market, commercialization efforts, their relationships with world renowned medical centers and strategic goals moving forward.


Recent Company Highlights

Uplisted shares of the company’s common stock to the Nasdaq Capital Market, under the ticker “BSGM”.Successfully raised a total of $13.5 million of capital, to finance upcoming operational milestones.Received a ‘Buy’ rating with $14.00/share price target from ROTH Capital Partners.Formed an Advisory Board to complement our existing Board of Directors and advise the Company leadership on a range of subjects, including financing, commercialization, government affairs and strategic partnerships.Announced that the company will be presenting the results from the First-in-Human studies and the early feedback from the use of its PURE EP(tm) System to a larger community of physicians, and other potential customers, in May 2019.


“As BioSig moves towards commercialization of our proprietary PURE EP(tm) System, we believe that now is an ideal time to update investors on the recent achievements the Company has made in establishing a platform capable of sustaining long-term growth,” stated Mr. Kenneth Londoner, Founder, Chairman and CEO of BioSig Technologies.  “The Company has fortified its balance sheet, uplisted to a more senior exchange, and expanded strategic relationships with some of the most recognizable names in the medical technology sector. We are at a key inflection point in the company’s growth trajectory and anticipate that 2019 will be a very significant year for us. We are well-positioned to execute on our early commercialization strategy and improve overall shareholder value.”